NovoRapid FlexPen Drug Interactions

A number of medicinal products are known to interact with glucose metabolism.
The following substances may reduce the patient's insulin requirements: Oral antidiabetic drugs, MAOIs, β-blockers, angiotensin-converting enzyme (ACE) inhibitors, salicylates, anabolic steroids and sulfonamides.
The following substances may increase the patient's insulin requirements: Oral contraceptives, thiazides, glucocorticoids, thyroid hormones, sympathomimetics, growth hormone and danazol.
Beta-blocking agents may mask the symptoms of hypoglycemia and delay recovery from hypoglycemia.
Octreotide/lanreotide may both increase and decrease insulin requirement.
Alcohol may intensify and prolong the glucose-lowering effect of insulin.
Incompatibilities: Substances added to NovoRapid may cause degradation of insulin aspart eg, if the product contains thiol or sulfites. This product must not be mixed with other products. Exceptions are NPH (Neutral Protamine Hagedorn) insulin and infusion fluids as described in Dosage & Administration.